Gastric Cancer, Stomach Neoplasms
Conditions
Keywords
Specialization, Postoperative Complications, Morbidity, Gastrectomy, Gastric Cancer
Brief summary
Specialization is having competent and effective knowledge on a subject, and the tendency towards specialization is increasing due to the fact that it increases the success in the follow-up and treatment process of diseases. It has been observed that specialization in cancer surgery provides significant improvement in clinical outcomes in recent years. In this study, the effect of specialization in gastric cancer surgery on clinical outcomes is being investigated.
Detailed description
Specialization is having sufficient and effective knowledge on a subject. Today, in the medical world, specialization is defined as having competent knowledge on a disease, and in recent years, the benefit of specialization has begun to be emphasized. Initially, it was defined as a branching and over the years, internal and surgical departments were divided into sub-areas. In surgical sciences, these fields are determined as traumatology, breast-endocrine surgery and gastrointestinal system surgery. This branching has brought a different perspective and approach to diseases and has made it possible to be more effective in the management of diseases. In recent years, a specialization approach on diseases and organ systems has developed within these branches. In surgery, surgeons specialized on many organs such as pancreatic surgery, colorectal surgery, gastric surgery, breast surgery, ovarian surgery have increased the efficiency in the management of diseases and the survival and disease-free survival rates of the patients have increased, and the postoperative morbidity and mortality rates have decreased. Gastric cancer is one of the most common malignant cancers. It is the fifth most common cause of cancer-related death worldwide. Despite advances in diagnosis and treatment methods, patients may still be diagnosed late, and patients still have a poor prognosis due to the biology of gastric cancer. Even in properly treated patients, five-year survival rates are around 20-30%. With the development of surgical techniques and disease management, clinical outcomes of the disease have improved and mortality has been reduced. In the studies, the definition of gastric surgeon was created and it was determined that the mortality decreased proportionally with the increase in the patient volume of the surgeon. In gastric cancer surgery, there are mostly studies on the number of surgeon patients and the number of hospital patients. Post-hoc analysis of hospital volume on patients included in the CRITICS study showed a 13.1% increase in survival in high-volume hospitals compared to low-volume hospitals. The number of annual resections ≥21 was determined as the definition of high-volume hospital. In addition, it was determined that there was a decrease in mortality as the number of annual cases increased in high-volume hospitals. In another study, it was seen that there was an improvement in the mortality of medium and high volume hospitals compared to low volume hospitals. The majority of studies in gastric cancer surgery have focused on hospital volume and surgeon volume. There are no data on the specialization of the surgeon other than a study based in Japan. In this study, it was aimed to evaluate the effect of specialization in gastric cancer surgery on short- and long-term clinical outcomes.
Interventions
OTHERSpecialization
* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea), * Who identified themselves as primarily gastric surgeons during the study period * Whose annual gastric cancer surgery volume is more than 21
Sponsors
Karadeniz Technical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* cStage I/II/III gastric cancer * Histologically proven gastric adenocarcinoma * Underwent surgery with curative intent
Exclusion criteria
* Under 18 years old * Patients with non-adenocarcinoma diagnosis * Emergency surgeries * The need for a thoracic approach * Patients with a history of non-gastric cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day mortality | 30 days after the operation (postoperative hospital stay ≤ 30 days) or operation to first discharge from hospital (postoperative hospital stay > 30 days) | Death from any cause within 30 days after surgery or at any time if not discharged from hospital |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 90-day mortality | 90 days after the operation (postoperative hospital stay ≤ 90 days) or operation to first discharge from hospital (postoperative hospital stay > 90 days) | Death from any cause within 90 days after surgery or at any time if not discharged from hospital |
| Postoperative complication rate | Within 30 days after the operation | Any complications (graded by the Clavien-Dindo classification) occurred in the postoperative period |
| Postoperative major complication rate | Within 30 days after the operation | ≥grade-III Clavien-Dindo complications occurred in the postoperative period |
| Readmission | Within 30 days after the operation | Readmission requiring re-hospitalization for any complications after discharge |
| 3-year recurrence-free survival | 3 years after surgery | Death from any cause or the recurrence of gastric cancer are an event. |
| Hospital stay | From the date of surgery until the date of hospital discharge, assessed up to 90 days after the operation | Duration of postoperative hospital stays |
| 3-year overall survival | 3 years after surgery | Death from any cause is defined as an event. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Failure-to-cure | Within 30 days after the operation | futile surgery due to intraoperative distant metastasis/irresectability, OR microscopically or macroscopically incomplete resection OR 30-day mortality |
| Neoadjuvant treatment usage | Within the three months before surgery | Neoadjuvant treatment usage rates in patients undergoing surgical treatment |
Countries
Turkey (Türkiye)
Outcome results
None listed